Evidence map›Paper›PMID 34176028›Full record

ArticleBiotechnology letters2021

The construction of a dual-functional strain that produces both polysaccharides and sulfotransferases.

Xiaomei Li, Yanying Yu, Jiaqing Tang, Bingxue Gong, Wenjing Li, Tingting Chen, Xianxuan Zhou

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Probiotic-Based Materials as Living Therapeutics.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xiaomei Li *School of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, 230009, China.
Yanying Yu *School of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, 230009, China.
Jiaqing TangSchool of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, 230009, China.
Bingxue GongSchool of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, 230009, China.
Wenjing LiSchool of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, 230009, China.
Tingting ChenSchool of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, 230009, China.
Xianxuan ZhouSchool of Biotechnology and Food Engineering, Hefei University of Technology, Hefei, 230009, China. zhoux@hfut.edu.cn.ORCID http://orcid.org/0000-0003-0105-5161
Hefei University of Technology · CN

Funding

National Natural Science Foundation of China 31670120
6 · The paper itself

Abstract

objectivesHeparosan is used as the starting polysaccharide sulfated using sulfotransferase to generate fully elaborate heparin, a widely used clinical drug. However, the preparation of heparosan and enzymes was considered tedious since such material must be prepared in separate fermentation batches. In this study, a commonly admitted probiotic, Escherichia coli strain Nissle 1917 (EcN), was engineered to intracellularly express sulfotransferases and, simultaneously, secreting heparosan into the culture medium.

resultsThe engineered strain EcN::T7M, carrying the λDE3 region of BL21(DE3) encoding T7 RNA polymerase, expressed the sulfotransferase domain (NST) of human N-deacetylase/N-sulfotransferase-1 (NDST-1) and the catalytic domain of mouse 3-O-sulfotransferase-1 (3-OST-1) in a flask. The fed-batch fermentation of EcN::T7M carrying the plasmid expressing NST was carried out, which brought the yield of NST to 0.21 g/L and the yield of heparosan to 0.85 g/L, respectively. Furthermore, the heparosan was purified, characterized by

conclusionsThese results indicate that EcN::T7M is capable of preparing sulfotransferase and heparosan at the same time. The EcN::T7M strain is also a suitable host for expressing exogenous proteins driven by tac promoter and T7 promoter.

Indexed as

AnimalsBatch Cell Culture TechniquesDisaccharidesEscherichia coliEscherichia coli ProteinsFermentationGenetic EngineeringHeparinHumansMiceProtein DomainsSulfotransferasesDisaccharidesEscherichia coli ProteinsHeparinheparitin sulfotransferaseheparosanSulfotransferasesEcNHeparinHeparosanSulfotransferaseT7 RNA polymerase

Identifiers

PMID34176028
OpenAlexW3174262017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.